Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index; 37 of the 67 sources its claims cite were checked for support.

Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species

Open access

Abstract

Fluconazole (FLC) is extensively employed for the prophylaxis and treatment of invasive fungal infections (IFIs). However, the fungistatic nature of FLC renders pathogenic fungi capable of developing tolerance towards it. Consequently, converting FLC into a fungicidal agent using adjuvants assumes significance to circumvent FLC resistance and the perpetuation of fungal infections. This drug repurposing study has successfully identified pitavastatin calcium (PIT) as a promising adjuvant for enhancing the fungicidal activity of FLC from a comprehensive library of 2372 FDA-approved drugs. PIT could render FLC fungicidal even at concentrations as low as 1 μM. The median lethal dose (LD50) of PIT was determined to be 103.6 mg/kg. We have discovered that PIT achieves its synergistic effect by inhibiting the activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, thereby impeding ubiquinone biosynthesis, inducing reactive oxygen species (ROS) generation, triggering apoptosis, and disrupting Golgi function. We employed a Candida albicans strain that demonstrated a notable tolerance to FLC to infect mice and found that PIT effectively augmented the antifungal efficacy of FLC against IFIs. This study is an illustrative example of how FDA-approved drugs can effectively eliminate fungal tolerance to FLC.

Overview

CoChat Summary

TL;DR

A screen of 2372 FDA-approved drugs identified pitavastatin calcium (PIT) as a fluconazole (FLC) adjuvant that converts FLC from fungistatic to fungicidal at low concentrations. PIT acts by inhibiting HMG-CoA reductase/ubiquinone biosynthesis, increasing ROS and apoptosis, disrupting Golgi function, and improving outcomes in mice infected with highly FLC-tolerant Candida albicans.

Key findings

  • From 2372 FDA-approved drugs, 222 prevented C. albicans recovery with 4 μg/mL FLC; after excluding 22 known antifungals, 200 were tested, 30 made FLC fungicidal below 12.5 μM, and 12 did so at ≤3.125 μM with FLC ≤4 μg/mL. Eight compounds cleared FLC tolerance in disk diffusion assays across four strains.
  • PIT had an LD50 of 103.6 mg/kg, compared with 19 mg/kg for GdA and 42 mg/kg for CsA. With 1 μM PIT, FLC MIC decreased from 1 to 0.5 μg/mL and MFC decreased from not detected up to 64 μg/mL to 2 μg/mL, giving MFC/MIC = 4. PIT also rendered voriconazole, ketoconazole, itraconazole, and miconazole fungicidal.
  • PIT targeted HMG-CoA reductase/Hmg1: HMG1/hmg1Δ, ERG8/erg8Δ, and IDI1/idi1Δ mutants were more susceptible to 4 μM PIT; HMG1 overexpression and exogenous mevalonate mitigated PIT. PIT + FLC increased intracellular and mitochondrial ROS about 2-fold, upregulated MCA1 about 7-fold vs control and 2.5-fold vs FLC alone, upregulated CYC3 about 15.7-fold vs control and 4.3-fold vs FLC alone, and increased caspase activity nearly 2-fold vs FLC alone. Ergosterol plus ubiquinone together reversed the synergistic lethality.
  • In mice infected with high FLC-tolerant cmp1-aidΔ/cmp1-aidΔ, FLC 1 mg/kg + PIT 0.5 mg/kg reduced kidney fungal burden (p = 0.0032 at day 6; p = 0.0023 at day 10). With clinical isolate 283, FLC 4 mg/kg + PIT 1 or 3 mg/kg reduced kidney burden (p = 0.0192 and p = 0.0054). Mortality over 30 days was 60% in controls, 50% with FLC alone, and 10% with FLC + PIT 3 mg/kg (p = 0.0204 vs control; p = 0.0477 vs FLC).

Methods

  • High-throughput screen of 2372 FDA-approved drugs at 100 μM with 4 μg/mL FLC against C. albicans SC5314, followed by broth microdilution, dose–matrix titration, disk diffusion, spotting, MFC determination, qRT-PCR, gene deletion/overexpression, ROS measurement, caspase assay, and membrane permeability assays.
  • Acute toxicity was assessed by the OECD 425 Up-and-Down procedure via intraperitoneal administration in mice to determine LD50.
  • Murine invasive candidiasis used female C57BL/6 mice (6–8 weeks old, 17–19 g) infected by tail vein with C. albicans strains or clinical isolate 283; FLC ± PIT was given intraperitoneally for 3 days, with survival monitored for 30 days, fungal burden measured in spleen/liver/kidney, and histopathology performed. Statistical analyses included two-tailed unpaired t-tests, Kaplan–Meier curves, and log-rank tests.

Limitations

  • Stated in the paper: “this study did not directly measure intracellular ergosterol levels,” although ergosterol-synthesis inhibition was supported by mevalonate rescue and gene-expression data.
  • Evident from the text: the in vivo work is limited to mouse models, with fungal-burden analyses using six mice per group and survival analyses using ten mice per group; no human clinical data are reported.
  • Evident from the text: the mechanism is inferred largely from genetic susceptibility, overexpression, and metabolite-rescue experiments; direct enzymatic measurement of Hmg1 activity or direct quantification of ubiquinone levels is not reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/antiox13060667

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 A screening process was conducted on the FDA-approved compound library, identifying 30 compounds that exhibit synergistic fungicidal properties against C. albicans when combined with FLC. The compounds exhibiting significant bioactivity at a synergistic lethal concentration lower than 12.5 μM are represented by red points.
Figure 1 A screening process was conducted on the FDA-approved compound library, identifying 30 compounds that exhibit synergistic fungicidal properties against C. albicans when combined with FLC. The compounds exhibiting significant bioactivity at a synergistic lethal concentration lower than 12.5 μM are represented by red points.CC BY · PubMed Central
Figure 2 Twelve compounds eliminated the trailing growth of C. albicans exposed to FLC, each with a concentration below 3.125 μM. Dose–matrix titration assays were conducted using these 12 compounds and FLC in a YPD medium at 30 °C for 48 h.
Figure 2 Twelve compounds eliminated the trailing growth of C. albicans exposed to FLC, each with a concentration below 3.125 μM. Dose–matrix titration assays were conducted using these 12 compounds and FLC in a YPD medium at 30 °C for 48 h.CC BY · PubMed Central
Figure 3 Eight compounds were identified from a pool of twelve candidate compounds to counteract the FLC tolerance exhibited by four strains subjected to testing. The FLC disk diffusion assays involved plating 1 × 106 cells from a subset of strains with varying levels of FLC tolerance. These cells were grown on a YPD solid medium, both with and without adjuvant, at 30 °C for 48 h. Subsequently, the cells were replica plated onto YPD plates (devoid of FLC or adjuvants) and incubated at 30 °C for 24 h, following the removal of the FLC disk.
Figure 3 Eight compounds were identified from a pool of twelve candidate compounds to counteract the FLC tolerance exhibited by four strains subjected to testing. The FLC disk diffusion assays involved plating 1 × 106 cells from a subset of strains with varying levels of FLC tolerance. These cells were grown on a YPD solid medium, both with and without adjuvant, at 30 °C for 48 h. Subsequently, the cells were replica plated onto YPD plates (devoid of FLC or adjuvants) and incubated at 30 °C for 24 h, following the removal of the FLC disk.CC BY · PubMed Central
Figure 4 PIT has low toxicity. (A) The LD50 of nine compounds were determined using the Up-and-Down procedure (UDP) administered via the intraperitoneal route in mice. The certain adjuvants CsA and GdA were regarded as the control drugs. (B) The chemical structure of PIT, the candidate FLC adjuvant.
Figure 4 PIT has low toxicity. (A) The LD50 of nine compounds were determined using the Up-and-Down procedure (UDP) administered via the intraperitoneal route in mice. The certain adjuvants CsA and GdA were regarded as the control drugs. (B) The chemical structure of PIT, the candidate FLC adjuvant.CC BY · PubMed Central
Figure 5 PIT confers fungicidal properties to azoles. (A) PIT makes FLC fungicidal. Two replicates are shown in the picture. (B) PIT confers fungicidal properties to voriconazole, ketoconazole, itraconazole, and miconazole. (C) MIC assays and spotting assays show that erg11∆/erg11∆ was significantly sensitive to PIT compared to the wild-type strain. (D) Supra-MIC growth (SMG) of FLC alone and in combination with PIT for C. albicans, Candida glabrata, and Candida guilliermondii.
Figure 5 PIT confers fungicidal properties to azoles. (A) PIT makes FLC fungicidal. Two replicates are shown in the picture. (B) PIT confers fungicidal properties to voriconazole, ketoconazole, itraconazole, and miconazole. (C) MIC assays and spotting assays show that erg11∆/erg11∆ was significantly sensitive to PIT compared to the wild-type strain. (D) Supra-MIC growth (SMG) of FLC alone and in combination with PIT for C. albicans, Candida glabrata, and Candida guilliermondii.CC BY · PubMed Central
Figure 6 (A) MIC assays and spotting assays show that feeding 100 μM exogenous (RS)-mevalonate lithium or ergosterol could counteract the antifungal activity of PIT in C. albicans SN152. (B) Dose–matrix titration assays indicated that 100 μM ergosterol counteracted the antifungal activity of FLC and PIT. (C) (Left) The diagrammatic sketch of ergosterol biosynthesis pathway in C. albicans. The different colored boxes represent the three modules: the mevalonate pathway is the blue box; the green box is composed of farnesyl pyrophosphate biosynthesis; and the final orange box contains ergosterol biosynthesis. (Right) Compared to the SN152 strain and other heterozygous gene deletion mutants, the HMG1/hmg1Δ, ERG8/erg8Δ, and IDI1/idi1Δ mutants are more susceptible to 4 μM PIT. (D) Spotting assays were performed on the solid YPD medium containing different concentrations of PIT (0, 2, 4, and 8 μM). Only over-expressed HMG1 gene could counteract the antifungal activity of PIT, rather than the ERG8 and the IDI1 genes.
Figure 6 (A) MIC assays and spotting assays show that feeding 100 μM exogenous (RS)-mevalonate lithium or ergosterol could counteract the antifungal activity of PIT in C. albicans SN152. (B) Dose–matrix titration assays indicated that 100 μM ergosterol counteracted the antifungal activity of FLC and PIT. (C) (Left) The diagrammatic sketch of ergosterol biosynthesis pathway in C. albicans. The different colored boxes represent the three modules: the mevalonate pathway is the blue box; the green box is composed of farnesyl pyrophosphate biosynthesis; and the final orange box contains ergosterol biosynthesis. (Right) Compared to the SN152 strain and other heterozygous gene deletion mutants, the HMG1/hmg1Δ, ERG8/erg8Δ, and IDI1/idi1Δ mutants are more susceptible to 4 μM PIT. (D) Spotting assays were performed on the solid YPD medium containing different concentrations of PIT (0, 2, 4, and 8 μM). Only over-expressed HMG1 gene could counteract the antifungal activity of PIT, rather than the ERG8 and the IDI1 genes.CC BY · PubMed Central
Figure 7 FLC, in combination with PIT, triggers ROS accumulation and induces apoptosis. (A) Dose–matrix titration assays hinted at the synergistic effect of FLC and PIT (FICI = 0.3125). (B) Spotting assays showed that the HMG1/hmg1∆ mutant was lethal under 16 μM PIT treatment and feeding 100 μM exogenous ergosterol could not fully regain the lethal activity. (C) Quantitative data of intracellular and mitochondrial ROS. After treatment with 4 μg/mL FLC and 2 μM PIT for 4 h, C. albicans cells were incubated with the fluorescent dye DCFH-DA or specific fluorescent dye MitoSOX Red at 30 °C for 30 min; then flow cytometry was employed. (D) The transcription levels of MCA1 and CYC3 in response to 4 μg/mL FLC and 2 μM PIT for 4 h were measured by qRT-PCR. (E) Determination of the caspase assay. After being treated with 4 μg/mL FLC and 2 μM PIT for 4 h, C. albicans cells were stained by (aspartyl)2-Rhodamine 110 (D2R) and analyzed by flow cytometry with excitation and emission wavelength at 488 and 530 nm, respectively. (F) Supplementation assays of ergosterol and ubiquinone. Dose–matrix titration assays indicated that 12.5 μM ergosterol and 1.5625 μM ubiquinone counteracted the antifungal activity of FLC and PIT. Then, the corresponding drug wells at that concentration were selected, and 100 μL per well was used to coat the YPD plate. The incubation time of the dose–matrix titration assays was 72 h, the incubation was continued for 48 h after coating the plates, and the incubation temperature was 30 °C in all cases. Three replications of this experiment were performed. (G) Quantification of supplementation assays of ergosterol and ubiquinone.
Figure 7 FLC, in combination with PIT, triggers ROS accumulation and induces apoptosis. (A) Dose–matrix titration assays hinted at the synergistic effect of FLC and PIT (FICI = 0.3125). (B) Spotting assays showed that the HMG1/hmg1∆ mutant was lethal under 16 μM PIT treatment and feeding 100 μM exogenous ergosterol could not fully regain the lethal activity. (C) Quantitative data of intracellular and mitochondrial ROS. After treatment with 4 μg/mL FLC and 2 μM PIT for 4 h, C. albicans cells were incubated with the fluorescent dye DCFH-DA or specific fluorescent dye MitoSOX Red at 30 °C for 30 min; then flow cytometry was employed. (D) The transcription levels of MCA1 and CYC3 in response to 4 μg/mL FLC and 2 μM PIT for 4 h were measured by qRT-PCR. (E) Determination of the caspase assay. After being treated with 4 μg/mL FLC and 2 μM PIT for 4 h, C. albicans cells were stained by (aspartyl)2-Rhodamine 110 (D2R) and analyzed by flow cytometry with excitation and emission wavelength at 488 and 530 nm, respectively. (F) Supplementation assays of ergosterol and ubiquinone. Dose–matrix titration assays indicated that 12.5 μM ergosterol and 1.5625 μM ubiquinone counteracted the antifungal activity of FLC and PIT. Then, the corresponding drug wells at that concentration were selected, and 100 μL per well was used to coat the YPD plate. The incubation time of the dose–matrix titration assays was 72 h, the incubation was continued for 48 h after coating the plates, and the incubation temperature was 30 °C in all cases. Three replications of this experiment were performed. (G) Quantification of supplementation assays of ergosterol and ubiquinone.CC BY · PubMed Central
Figure 8 PIT made FLC fungicidal by disrupting membrane integrity. (A) The nucleic acid leakage in C. albicans SN152 after 4 μg/mL FLC, 2 μM PIT alone, and FLC and PIT combination for 4 h. Amphotericin B (2 μM) was regarded as the positive control. (B) The extracellular protein content in C. albicans SN152 after 4 μg/mL FLC, 2 μM PIT alone, and FLC and PIT combination for 4 h. Amphotericin B (2 μM) was regarded as the positive control. (C) MIC assays in YPD medium with PIT (0, 0.5, 1 μM) showed that the age3Δ/age3Δ mutant was more sensitive to FLC than other strains. (D) The age3Δ/age3Δ strain showed significant sensitivity to the combination of FLC and PIT using spotting assay analysis.
Figure 8 PIT made FLC fungicidal by disrupting membrane integrity. (A) The nucleic acid leakage in C. albicans SN152 after 4 μg/mL FLC, 2 μM PIT alone, and FLC and PIT combination for 4 h. Amphotericin B (2 μM) was regarded as the positive control. (B) The extracellular protein content in C. albicans SN152 after 4 μg/mL FLC, 2 μM PIT alone, and FLC and PIT combination for 4 h. Amphotericin B (2 μM) was regarded as the positive control. (C) MIC assays in YPD medium with PIT (0, 0.5, 1 μM) showed that the age3Δ/age3Δ mutant was more sensitive to FLC than other strains. (D) The age3Δ/age3Δ strain showed significant sensitivity to the combination of FLC and PIT using spotting assay analysis.CC BY · PubMed Central
Figure 9 PIT enhances the antifungal activity of FLC against C. albicans in vivo. (A) Schematic overview of the timeline for the systemic candidiasis model. (B) CFUs analysis of infected liver, kidney, and spleen tissues after being infected for 6 or 10 days. C57BL/6 mice were intravenously infected with cmp1Δ/cmp1Δ (no FLC tolerance) and cmp1-aidΔ/cmp1-aidΔ (high FLC tolerance). FLC was administered at 1 mg/kg intraperitoneally once daily and lasted three days. CFUs were normalized to tissue weight (n = 6). p values were calculated using two-tailed unpaired t-tests. (C) Histopathology analysis of infected kidney tissues after 6 or 10 days of infection. Infected kidney tissues were stained with Periodic Acid-Schiff (PAS) and examined under ×1, ×3, and ×10 lenses (Scale bar = 1 mm, 250 μm, and 50 μm). Stained fungal cells are indicated with red arrows. Data were obtained from three independent experiments, and representative images are shown. (D) CFUs analysis of infected liver, kidney, and spleen tissues after 6 or 10 days of infection. C57BL/6 mice were intravenously infected with cmp1-aidΔ/cmp1-aidΔ. All values are CFUs recovered from tissue homogenates after 3 days of treatment. FLC was administered at 1 mg/kg and PIT at 0.5 mg/kg intraperitoneally once daily. CFUs were normalized to tissue weight (n = 6). p values were calculated using two-tailed unpaired t-tests.
Figure 9 PIT enhances the antifungal activity of FLC against C. albicans in vivo. (A) Schematic overview of the timeline for the systemic candidiasis model. (B) CFUs analysis of infected liver, kidney, and spleen tissues after being infected for 6 or 10 days. C57BL/6 mice were intravenously infected with cmp1Δ/cmp1Δ (no FLC tolerance) and cmp1-aidΔ/cmp1-aidΔ (high FLC tolerance). FLC was administered at 1 mg/kg intraperitoneally once daily and lasted three days. CFUs were normalized to tissue weight (n = 6). p values were calculated using two-tailed unpaired t-tests. (C) Histopathology analysis of infected kidney tissues after 6 or 10 days of infection. Infected kidney tissues were stained with Periodic Acid-Schiff (PAS) and examined under ×1, ×3, and ×10 lenses (Scale bar = 1 mm, 250 μm, and 50 μm). Stained fungal cells are indicated with red arrows. Data were obtained from three independent experiments, and representative images are shown. (D) CFUs analysis of infected liver, kidney, and spleen tissues after 6 or 10 days of infection. C57BL/6 mice were intravenously infected with cmp1-aidΔ/cmp1-aidΔ. All values are CFUs recovered from tissue homogenates after 3 days of treatment. FLC was administered at 1 mg/kg and PIT at 0.5 mg/kg intraperitoneally once daily. CFUs were normalized to tissue weight (n = 6). p values were calculated using two-tailed unpaired t-tests.CC BY · PubMed Central
Figure 10 PIT strengthens the antifungal activity of FLC against clinically relevant C. albicans in vivo. (A) CFU analysis of infected liver, kidney, and spleen tissues after 6 days of infection. C57BL/6 mice were infected with 283 cells of C. albicans via tail vein injection. All values are CFUs recovered from tissue homogenates after 3 days of treatment. FLC was administered at 4 mg/kg and PIT at 1 or 3 mg/kg intraperitoneally once daily. CFUs were normalized to tissue weight (n = 6). p values were calculated using two-tailed unpaired t-tests. (B) The weight of C57BL/6 mice was monitored once every 3 days for 15 days. Two-tailed, unpaired t-tests and two-way ANOVAs were used. (C) C57BL/6 mice were monitored for the health and survival of treated (green and blue) and untreated (red) mice for 30 days. Significance was determined using the log-rank (Mantel–Cox) test.
Figure 10 PIT strengthens the antifungal activity of FLC against clinically relevant C. albicans in vivo. (A) CFU analysis of infected liver, kidney, and spleen tissues after 6 days of infection. C57BL/6 mice were infected with 283 cells of C. albicans via tail vein injection. All values are CFUs recovered from tissue homogenates after 3 days of treatment. FLC was administered at 4 mg/kg and PIT at 1 or 3 mg/kg intraperitoneally once daily. CFUs were normalized to tissue weight (n = 6). p values were calculated using two-tailed unpaired t-tests. (B) The weight of C57BL/6 mice was monitored once every 3 days for 15 days. Two-tailed, unpaired t-tests and two-way ANOVAs were used. (C) C57BL/6 mice were monitored for the health and survival of treated (green and blue) and untreated (red) mice for 30 days. Significance was determined using the log-rank (Mantel–Cox) test.CC BY · PubMed Central
Figure 11 Identification of PIT as a promising FLC synergistic lethal adjuvant, thereby augmenting the efficacy of FLC in managing IFIs caused by highly FLC-tolerant strains.
Figure 11 Identification of PIT as a promising FLC synergistic lethal adjuvant, thereby augmenting the efficacy of FLC in managing IFIs caused by highly FLC-tolerant strains.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 3 Not valid · 7 Not checked · 95 Own results and interpretations

79 more claims · 5 with their cited sources checked

Create a free account to see all 128 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 32
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 80 references

Cited by

See all 14

Metadata

Authors
Li, W., Feng, Y., Feng, Z., Wang, L., Whiteway, M., Lu, H., & Jiang, Y.
Affiliations
  • Tongji University (CN)
  • Concordia University (CA)
Corresponding author
  • Lu, Hui
  • Jiang, Yuanying
Venue
Antioxidants
Publisher
MDPI AG
Published
2024-05-29
Volume
13
Issue
6
Pages
667
ISSN
2076-3921 (ISSN-L)
OpenAlex
W4399217048
Cited by
14
References
80
Citations by year
2026: 6 · 2025: 7 · 2024: 1
FWCI
4.81
Type
journal article
Language
en
Open access
Locations
  • Antioxidants (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Key Research and Development Program of China (2022YFC2303004, 2021YFC2300404, 82020108032, 202101070007-E00094)
  • National Natural Science Foundation of China (2022YFC2303004, 2021YFC2300404, 82020108032, 202101070007-E00094)
  • Innovation Program of Shanghai Municipal Education Commission (2022YFC2303004, 2021YFC2300404, 82020108032, 202101070007-E00094)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
fluconazole, drug repurposing, fungicidal activity, drug synergy, HMG-CoA reductase inhibition, ubiquinone biosynthesis, reactive oxygen species, apoptosis, Golgi function, Candida albicans, invasive fungal infections, antifungal resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species. https://app.cochat.ai/papers/10.3390/antiox13060667
The paper
Li, W., Feng, Y., Feng, Z., Wang, L., Whiteway, M., Lu, H., & Jiang, Y. (2024). Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species. Antioxidants. https://doi.org/10.3390/antiox13060667

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.